Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults
Robert H HowlandUniversity of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh PA, USAAbstract: This article describes the pharmacology of the novel atypical antidepressant drug agomelatine, critically reviews and evaluates...
Guardado en:
Autor principal: | Robert H Howland |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/23a2b41228854a5b80313ff0848d632a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Agomelatine as monotherapy for major depression: an outpatient, open-label study
por: Pecenak J, et al.
Publicado: (2013) -
Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
por: Pecenak J, et al.
Publicado: (2013) -
Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study
por: Fornaro M, et al.
Publicado: (2013) -
Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
por: Singh M, et al.
Publicado: (2012) -
Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
por: Levitan MN, et al.
Publicado: (2015)